Research programme: anticancer therapeutics - Biolojic Design
Latest Information Update: 03 Nov 2023
At a glance
- Originator Biolojic Design
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Sep 2023 Anticancer therapeutics - Biolojic Design is available for licensing as of 27 Sep 2023. https://biolojic.com/partnerships/ (Biolojic Design website, September 2023)
- 27 Sep 2023 Preclinical trials in Cancer in Israel (Parenteral) before September 2023 (Biolojic Design pipeline, September 2023)
- 01 Dec 2022 Biolojic Design has patent related to dual binding antibodies, methods of producing dual binding antibodies